Neuroinflammatory Disorders in Kathmandu — Beyond Multiple Sclerosis

Neuroinflammatory disorders encompass a spectrum of conditions where immune-mediated inflammation affects the central nervous system. While multiple sclerosis is the most recognized, other important conditions include neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease, acute disseminated encephalomyelitis (ADEM), and neurosarcoidosis. Accurate diagnosis is critical because treatment approaches differ significantly between these conditions.

Neuromyelitis optica spectrum disorder (NMOSD) was previously called Devic's disease. It is characterized by attacks of optic neuritis (inflammation of the optic nerve causing vision loss) and transverse myelitis (inflammation of the spinal cord causing weakness, sensory loss, and bladder dysfunction). Unlike MS, NMOSD attacks are often more severe and recovery may be incomplete. The discovery of aquaporin-4 (AQP4) antibodies revolutionized diagnosis — approximately 70-80% of NMOSD patients test positive for this antibody. Treatment focuses on preventing relapses with medications such as rituximab, mycophenolate, or azathioprine, rather than the disease-modifying therapies used for MS.

Dr. Jitendra Prasad Yadav — consultant neurologist & headache specialist at Kathmandu Neurology Clinic & Cognitive Center provides evidence-based evaluation for multiple sclerosis.

MOG antibody-associated disease is a relatively recently recognized condition that shares features with both MS and NMOSD. Patients typically present with optic neuritis, transverse myelitis, or ADEM-like encephalitis. MOG antibodies are present in the blood or CSF. The disease course is variable — some patients have a monophasic illness (single attack), while others have relapses. Treatment during acute attacks involves corticosteroids and sometimes plasma exchange. Relapse prevention may involve rituximab, mycophenolate, or intravenous immunoglobulin, though optimal treatment protocols are still being studied.

Acute disseminated encephalomyelitis (ADEM) typically occurs in children, often after infection or vaccination. It causes widespread demyelination in the brain and spinal cord, presenting with encephalopathy (altered mental status), weakness, sensory changes, and sometimes optic neuritis. ADEM is usually monophasic, meaning it occurs as a single episode without relapse. Treatment involves high-dose corticosteroids during the acute phase.

Neurosarcoidosis involves granulomatous inflammation affecting the nervous system, occurring as part of systemic sarcoidosis. It can affect any part of the nervous system — cranial nerves (causing facial weakness or double vision), the pituitary gland (causing hormonal disturbances), the meninges (causing headache and meningitis), or the brain and spinal cord parenchyma. Diagnosis requires evidence of systemic sarcoidosis (typically on chest imaging showing hilar lymphadenopathy) plus neurological involvement. Treatment involves corticosteroids and often steroid-sparing immunosuppressants.

Diagnosis of neuroinflammatory disorders requires a combination of clinical evaluation, MRI brain and spinal cord, CSF analysis, and antibody testing. The pattern of MRI lesions (location, size, enhancement pattern) helps distinguish between conditions. CSF analysis may show oligoclonal bands in MS but typically not in NMOSD or MOG disease. Antibody testing for AQP4 and MOG is essential when these conditions are suspected.

At Kathmandu Neurology Clinic & Cognitive Center, Dr. Jitendra Prasad Yadav (NMC 8029) evaluates suspected neuroinflammatory disorders with comprehensive testing to achieve accurate diagnosis, as treatment differs significantly between conditions. Coordination with rheumatology and ophthalmology is often needed for optimal management.

This article is educational and does not replace individual medical advice.

**Frequently Asked Questions**

Q: What is the difference between MS and NMOSD? A: MS and NMOSD are distinct conditions with different pathophysiology, treatment, and prognosis. NMOSD attacks tend to be more severe and often involve the optic nerves and spinal cord selectively. AQP4 antibody testing helps distinguish them. Importantly, some MS medications can worsen NMOSD, making accurate diagnosis critical.

Q: Is MOG antibody disease the same as MS? A: No, MOG antibody disease is a distinct condition from MS. While both can cause optic neuritis and myelitis, MOG disease has different antibody targets, different MRI patterns, and may have a different treatment approach. Some patients with MOG disease have a monophasic course without relapses.

Q: How are neuroinflammatory disorders diagnosed? A: Diagnosis involves clinical evaluation, MRI brain and spinal cord, CSF analysis, and antibody testing (AQP4, MOG). The pattern of clinical features, imaging findings, and laboratory results helps distinguish between different neuroinflammatory conditions.

Q: What treatments are used for neuroinflammatory disorders? A: Treatment varies by condition. MS uses disease-modifying therapies such as interferons, oral medications, or monoclonal antibodies. NMOSD and MOG disease are typically treated with immunosuppressants like rituximab or mycophenolate. Acute attacks in all conditions are treated with corticosteroids and sometimes plasma exchange.

Q: Can neuroinflammatory disorders be cured? A: There is no cure for most neuroinflammatory disorders, but treatments can significantly reduce relapse frequency and disability. Some conditions like ADEM are typically monophasic. Ongoing research continues to improve treatment options and outcomes.

Q: When should neuroinflammatory disease be suspected? A: Neuroinflammatory disease should be suspected when there are episodes of neurological dysfunction affecting different parts of the nervous system over time, particularly when optic neuritis (vision loss), transverse myelitis (spinal cord inflammation), or unexplained encephalopathy occur. Prompt evaluation is important for accurate diagnosis and appropriate treatment.